TCT 234: Sex Differences in the Safety and Efficacy of Short-term DAPT Versus DAPT De-escalation After Percutaneous Coronary Intervention

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Abbott
• Consultant Fee/Honoraria/Speaker's Bureau - Amgen; AstraZenca; Bard Medical; Biotronik; Boehringer Ingelheim; Boston Scientific Corporation; Daiichi-Sankyo/Elil Lilly and Company; Medtronic; Pfizer; Terumo Medical Corporation; Abbott